Promising Response with PI3K Inhibitor for a Patient with Heavily Pretreated PIK3CA Mutation Head-and-Neck Cancer
The treatment options for patients with head-and-neck squamous cell carcinoma (HNSCC) are limited when the disease progresses after taking platinum, a PD-1 inhibitor, and cetuximab. To develop new agents for managing such pretreated malignancies, therapies targeting carcinogenic pathways could be po...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-04-01
|
| Series: | Journal of Cancer Research and Practice |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-22-00018 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591064844730368 |
|---|---|
| author | Ming-Jing Lee Hsiang-Fong Kao |
| author_facet | Ming-Jing Lee Hsiang-Fong Kao |
| author_sort | Ming-Jing Lee |
| collection | DOAJ |
| description | The treatment options for patients with head-and-neck squamous cell carcinoma (HNSCC) are limited when the disease progresses after taking platinum, a PD-1 inhibitor, and cetuximab. To develop new agents for managing such pretreated malignancies, therapies targeting carcinogenic pathways could be possible in HNSCC patients. Several pathways have been identified in HNSCC, including the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway. The PI3K/AKT/mTOR pathway is frequently dysregulated in various cancers due to activating mutations or amplification of PIK3CA. The inhibition of this pathway has been proven to improve clinical outcomes in some malignancies with PIK3CA mutations. We report a heavily pretreated HNSCC patient with a good treatment response to alpelisib, a PI3K inhibitor. Furthermore, we discuss the possible limitations of alpelisib monotherapy and possible solutions to overcome these limitations. |
| format | Article |
| id | doaj-art-dca93b60dab844a89cb977d4cc85dbce |
| institution | Kabale University |
| issn | 2311-3006 |
| language | English |
| publishDate | 2023-04-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Cancer Research and Practice |
| spelling | doaj-art-dca93b60dab844a89cb977d4cc85dbce2025-01-23T05:05:04ZengWolters Kluwer Medknow PublicationsJournal of Cancer Research and Practice2311-30062023-04-01102757710.4103/ejcrp.eJCRP-D-22-00018Promising Response with PI3K Inhibitor for a Patient with Heavily Pretreated PIK3CA Mutation Head-and-Neck CancerMing-Jing LeeHsiang-Fong KaoThe treatment options for patients with head-and-neck squamous cell carcinoma (HNSCC) are limited when the disease progresses after taking platinum, a PD-1 inhibitor, and cetuximab. To develop new agents for managing such pretreated malignancies, therapies targeting carcinogenic pathways could be possible in HNSCC patients. Several pathways have been identified in HNSCC, including the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway. The PI3K/AKT/mTOR pathway is frequently dysregulated in various cancers due to activating mutations or amplification of PIK3CA. The inhibition of this pathway has been proven to improve clinical outcomes in some malignancies with PIK3CA mutations. We report a heavily pretreated HNSCC patient with a good treatment response to alpelisib, a PI3K inhibitor. Furthermore, we discuss the possible limitations of alpelisib monotherapy and possible solutions to overcome these limitations.https://journals.lww.com/10.4103/ejcrp.eJCRP-D-22-00018alpelisibhead and neck squamous cell carcinomapik3ca mutation |
| spellingShingle | Ming-Jing Lee Hsiang-Fong Kao Promising Response with PI3K Inhibitor for a Patient with Heavily Pretreated PIK3CA Mutation Head-and-Neck Cancer Journal of Cancer Research and Practice alpelisib head and neck squamous cell carcinoma pik3ca mutation |
| title | Promising Response with PI3K Inhibitor for a Patient with Heavily Pretreated PIK3CA Mutation Head-and-Neck Cancer |
| title_full | Promising Response with PI3K Inhibitor for a Patient with Heavily Pretreated PIK3CA Mutation Head-and-Neck Cancer |
| title_fullStr | Promising Response with PI3K Inhibitor for a Patient with Heavily Pretreated PIK3CA Mutation Head-and-Neck Cancer |
| title_full_unstemmed | Promising Response with PI3K Inhibitor for a Patient with Heavily Pretreated PIK3CA Mutation Head-and-Neck Cancer |
| title_short | Promising Response with PI3K Inhibitor for a Patient with Heavily Pretreated PIK3CA Mutation Head-and-Neck Cancer |
| title_sort | promising response with pi3k inhibitor for a patient with heavily pretreated pik3ca mutation head and neck cancer |
| topic | alpelisib head and neck squamous cell carcinoma pik3ca mutation |
| url | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-22-00018 |
| work_keys_str_mv | AT mingjinglee promisingresponsewithpi3kinhibitorforapatientwithheavilypretreatedpik3camutationheadandneckcancer AT hsiangfongkao promisingresponsewithpi3kinhibitorforapatientwithheavilypretreatedpik3camutationheadandneckcancer |